A planning committee of the National Academies of Sciences, Engineering, and Medicine, will organize and conduct a two-day public workshop to examine and highlight the bottlenecks to innovation in drug research and development (R&D) for prevalent chronic diseases and consider challenges and opportunities for spurring drug R&D in this space.
The public workshop will feature invited presentations and discussions to:

• Discuss the unique cross-cutting challenges for spurring early stage innovation in drug R&D for prevalent chronic diseases (e.g. do we have promising targets?)
• Consider whether incentives are in alignment for spurring the type of product development that will address unmet need when it comes to prevalent chronic diseases (e.g., do we have the right business models in place?)
• Consider lessons learned from other disease areas (e.g., rare diseases) and/or use cases that could have cross-cutting applications for prevalent chronic diseases.
• Discuss considerations and/or strategies to spur drug R&D innovation for prevalent chronic diseases (i.e., determine whether there are promising avenues forward that merit additional time/effort/funding/attention).

The planning committee will organize the workshop, develop the agenda, select and invite speakers and discussants, and moderate or identify moderators for the discussions. A proceedings of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.